Beyond Inhibition: Recent Advances of Heterobifunctional Molecules Targeting CDK9

Area of Science:

• Molecular Biology
• Cancer Therapeutics
• Drug Discovery

Background:

• Cyclin-dependent kinase 9 (CDK9) is crucial for regulating genes involved in cancer, making it a key therapeutic target.
• Existing CDK9 inhibitors face challenges in clinical use, including limited effectiveness and drug resistance.
• Targeted protein degradation (TPD) presents a novel strategy to overcome these limitations.

Purpose of the Study:

• To explore the potential of TPD strategies, specifically Proteolysis-targeting Chimeras (PROTACs), for targeting CDK9.
• To investigate how PROTACs can induce CDK9 ubiquitination and degradation to achieve sustained antitumor effects.
• To evaluate innovative heterobifunctional molecules for targeting CDK9 through multiple mechanisms.

Main Methods:

• Development and application of PROTACs designed to induce CDK9 degradation.
• Investigation of heterobifunctional molecules targeting CDK9.
• Assessment of preclinical efficacy and resistance mechanisms in cancer models.

Main Results:

• PROTACs demonstrated potent and sustained antitumor activity against CDK9-dependent cancers.
• TPD strategies effectively overcame resistance mechanisms, such as MYC upregulation.
• Exploration of diverse molecular modalities expanded therapeutic targeting options for CDK9.

Conclusions:

• Targeted protein degradation, particularly PROTACs, offers a promising approach to overcome limitations of traditional CDK9 inhibitors.
• These advanced strategies hold potential for a new era in treating transcriptionally addicted cancers.
• Further development of heterobifunctional molecules targeting CDK9 could significantly advance cancer therapy.